Veraxa Secures $27.5M Secured Note and $50M Equity Line After Near-Total SPAC Redemptions
Distressed
Company Background
Veraxa Biotech AG is a Swiss oncology company developing next-generation cancer therapies — bispecific T-cell engagers and antibody-drug conjugates — built on scientific foundations from the European Molecular Biology Laboratory. It agreed in April 2025 to merge with Voyager Acquisition Corp., a Nasdaq-listed SPAC (ticker: VACH), with merger consideration subsequently increased to $1.35 billion in February 2026. Upon closing, the combined entity will be called Veraxa Biotech Holding AG and is expected to trade on Nasdaq under the ticker VRXA.
The transaction hit a severe structural obstacle at the March 12, 2026 shareholder vote: holders of 25,217,315 Class A ordinary shares — approximately 99.67% of all Class A shares outstanding — exercised their right to redeem, leaving only approximately $885,556 in the SPAC's trust account. Only 82,685 Class A shares will convert into shares of the combined company. The vote itself approved the merger; the problem is that almost nothing remains in the treasury.
As of the May 27, 2026 filing date, the merger has not yet closed, pending Nasdaq listing approval and other customary conditions. The two financings disclosed represent Veraxa's answer to entering public life with a trust account that is, for practical purposes, empty.
What Was Disclosed
On May 27, 2026, Veraxa Biotech Holding AG (PubCo), Veraxa Biotech AG, and Voyager entered into a securities purchase agreement with an undisclosed institutional investor for a private placement of two instruments: senior secured notes with an aggregate principal amount of $27,500,000, due August 27, 2027, plus warrants to purchase up to 2,391,305 ordinary shares at an initial exercise price of $11.50 per share — all for an aggregate purchase price of approximately $24.1 million. The difference between face value and purchase price reflects the effective discount at which the notes were sold. Funding occurs concurrently with the closing of the Business Combination.
The note terms are onerous. Amortization payments of $2,750,000 per month begin three months after the closing of the Business Combination, payable in cash or, at PubCo's election and subject to equity conditions, in registered shares. The notes carry a 20% cash sweep provision requiring PubCo to apply one-fifth of gross proceeds from any subsequent equity raise to note principal redemption. In the event of default, interest accrues at 15% per annum and the notes accelerate at 115% of outstanding principal plus accrued interest. PubCo grants a first-priority security interest in all tangible and intangible assets to a collateral agent, perfected through bank account pledge and control agreements.
Separately and simultaneously, PubCo entered into a purchase agreement with Lincoln Park Capital Fund, LLC, under which Lincoln Park committed to purchase up to $50,000,000 of PubCo ordinary shares over a 24-month period following the merger closing and SEC registration statement effectiveness. As consideration for that commitment, PubCo will issue Lincoln Park $750,000 in commitment shares on the business day before the initial registration statement is filed — earned in full regardless of whether any shares are subsequently sold. The purchase price for each draw is set at 97% of the lower of the daily low sale price or the average of the three lowest closing prices in the prior ten business days, a structure that embeds a persistent discount to market in every transaction.
Why It Matters
The near-total redemption left the trust account with roughly $885,000 — less than three days of amortization payments under the new note. The combined company will begin its public life with its $1.35 billion merger valuation supported almost entirely by these two new capital facilities rather than any cash from the SPAC process. The $27.5 million note provides a fixed pool of immediate capital but begins amortizing aggressively within three months of closing, and the 20% cash sweep means that any subsequent equity raise immediately diverts a portion back to the noteholder.
The Lincoln Park facility offers flexibility — PubCo controls timing and amount — but the pricing mechanics guarantee that every draw dilutes existing shareholders below the prevailing market price. The $750,000 in commitment shares represents an upfront fee paid regardless of utilization. Together, the two facilities reflect the menu of options available to a pre-revenue biotech that finds itself emerging from a SPAC with minimal cash: secured debt at a discount to face with stiff covenants, plus an at-the-market drip-feed equity line.
There are partial offsets. PubCo retains the right to make amortization payments in shares rather than cash when equity conditions are satisfied, easing near-term cash pressure. The note can be redeemed at par at any time without penalty. And the Lincoln Park agreement expressly prohibits Lincoln Park from short-selling or hedging PubCo shares, removing one common criticism of such structures. Whether $27.5 million is sufficient to sustain a clinical-stage oncology pipeline through meaningful data readouts — the stated purpose — is not addressed in the filing.